Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer

F. Xu, J. Xia, Y. Fu, Y. Yang, X. Chen, X. Li, Y. Zhou, J. Li, K. Dalhoff, H. Shen (Hangzhou, China; Rochester, United States Of America; Luebeck, Germany)

Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs
Session: Lung cancer and other malignant diseases involving the lungs
Session type: Thematic Poster Session
Number: 621
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Xu, J. Xia, Y. Fu, Y. Yang, X. Chen, X. Li, Y. Zhou, J. Li, K. Dalhoff, H. Shen (Hangzhou, China; Rochester, United States Of America; Luebeck, Germany). Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer. Eur Respir J 2008; 32: Suppl. 52, 621

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of adhesion molecule CEACAM1 and chemokine receptor CXCR4 expression on prognosis of non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 324s
Year: 2005

NTHi-promoted proliferation of K-ras-induced early lung cancer lesions is fully dependent on Toll-like receptor signaling
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017

Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines
Source: Annual Congress 2010 - Pathology of lung cancer
Year: 2010

KPNB1-mediated PD-L1 nuclear translocation promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signalling pathway
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020

Differences in growth signaling pathway activation in small cell and non-small cell carcinomas of the lung
Source: Eur Respir J 2006; 28: Suppl. 50, 326s
Year: 2006

Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019


Transcriptional regulation of the human osteopontin promoter in non-small cell lung cancer
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011

Bile acid receptor mediates cancer-associated fibroblasts-induced migration and invasion of non-small cell lung cancer cells
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017

CDCA promotes non-small-cell lung cancer (NSCLC) migration by regulating Akt/Erk1/2 signaling pathways
Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology
Year: 2019

Salinomycin suppresses TGF-ß1-induced EMT by down-regulating MMP-2,9 via AMPK-SIRT1 pathway in a non-small cell lung cancer
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017

Relationship between Cancer-associated fibroblast and programmed death ligand 1 expression in non-small cell lung cancer
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020

The death receptor Fas in CD3+T cells in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 673s
Year: 2004

Choice of endogenous control for gene expression in nonsmall cell lung cancer
Source: Eur Respir J 2005; 26: 1002-1008
Year: 2005



Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015


IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer
Source: Eur Respir J , 49 (4)  1600711; DOI: 10.1183/13993003.00711-2016
Year: 2017



HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line
Source: Annual Congress 2007 - Biology in thoracic oncology
Year: 2007


Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018
Year: 2019



Association of KIR genes and their ligands with non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010

Alpha and beta estrogen and progesterone receptors expression in non-small cell lung cancer patients
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008


Deguelin enhances chemosensitivity of non-small cell lung cancer cells
Source: Eur Respir J 2006; 28: Suppl. 50, 336s
Year: 2006